RxDoctor Payments DataLook up a doctor →

Navid Nami, DO

Dermatology · Newport Beach, CANPI 1710936646

Payments from drug & device makers

$2,199,210in general payments, 2019–2025

Across 732 payments — averaging $3004.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$938K
  • AbbVie$556K
  • LEO Pharma AS$439K
  • Amgen$141K
  • Galderma Laboratories, L.p.$43K
  • E.r. Squibb & Sons, L.L.C.$42K
  • plus $39K from 28 others
$51,482in research payments, 2019–2025

Across 5 payments — averaging $10,296 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Galderma Research & Development, LLC$29K
  • Eli Lilly$23K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,199,210 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$214,443
Medicare patients
498
Services billed
3,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →